Redhill Biopharma (RDHL)
(Delayed Data from NSDQ)
$0.46 USD
0.00 (-0.04%)
Updated May 31, 2024 03:56 PM ET
After-Market: $0.45 -0.01 (-1.77%) 7:58 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Redhill Biopharma Ltd. [RDHL]
Reports for Purchase
Showing records 61 - 80 ( 228 total )
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
TALICIA will dominate newsflow in H219
Provider: Edison Investment Research Limited
Analyst: PECIULIS J
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
All Eyes on Potential Talicia Approval in 4Q19; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
FDA Decision on Talicia Approval by November 2; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
TALICIA launch for H. pylori in sight
Provider: Edison Investment Research Limited
Analyst: PECIULIS J
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Talicia on Track for Approval in 4Q19; Pivotal NTM Study to Start; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Focus on Talicia; Adjusting PT to $16.00 on Changes to RHB-104 Outlook; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
Multiple Regulatory and Commercial Milestones Expected in 2019; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
TALICIA Ph III top-line data positive
Provider: Edison Investment Research Limited
Analyst: PECIULIS J
Company: Redhill Biopharma Ltd.
Industry: Medical - Drugs
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.